Kairos Pharma Statistics

Total Valuation

Kairos Pharma has a market cap or net worth of $11.27 million. The enterprise value is $7.66 million.

Market Cap	11.27M
Enterprise Value	7.66M

Important Dates

The next estimated earnings date is Saturday, August 23, 2025, before market open.

Earnings Date	Aug 23, 2025
Ex-Dividend Date	n/a

Share Statistics

Kairos Pharma has 16.85 million shares outstanding. The number of shares has increased by 21.51% in one year.

Current Share Class	16.85M
Shares Outstanding	16.85M
Shares Change (YoY)	+21.51%
Shares Change (QoQ)	+18.59%
Owned by Insiders (%)	46.03%
Owned by Institutions (%)	1.03%
Float	6.22M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.48
P/TBV Ratio	1.62
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.52

Current Ratio	7.52
Quick Ratio	4.49
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-21.71

Financial Efficiency

Return on equity (ROE) is -149.74% and return on invested capital (ROIC) is -77.01%.

Return on Equity (ROE)	-149.74%
Return on Assets (ROA)	-46.61%
Return on Invested Capital (ROIC)	-77.01%
Return on Capital Employed (ROCE)	-46.58%
Revenue Per Employee	n/a
Profits Per Employee	-$885,500
Employee Count	4
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	0.67
200-Day Moving Average	n/a
Relative Strength Index (RSI)	55.39
Average Volume (20 Days)	2,210,025

Short Selling Information

The latest short interest is 344,846, so 2.05% of the outstanding shares have been sold short.

Short Interest	344,846
Short Previous Month	6,937
Short % of Shares Out	2.05%
Short % of Float	5.54%
Short Ratio (days to cover)	0.02

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-3.32M
Pretax Income	-812,000
Net Income	-3.54M
EBITDA	-3.16M
EBIT	-3.32M
Earnings Per Share (EPS)	-$0.28

Full Income Statement

Balance Sheet

The company has $3.62 million in cash and n/a in debt, giving a net cash position of $3.62 million or $0.21 per share.

Cash & Cash Equivalents	3.62M
Total Debt	n/a
Net Cash	3.62M
Net Cash Per Share	$0.21
Equity (Book Value)	7.13M
Book Value Per Share	0.45
Working Capital	5.25M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-4.71M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kairos Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-21.51%
Shareholder Yield	-21.51%
Earnings Yield	-31.42%
FCF Yield	n/a

Analyst Forecast

The average price target for Kairos Pharma is $8.33, which is 1,145.14% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$8.33
Price Target Difference	1,145.14%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1